European Union - English - EMA (European Medicines Agency)

glaxosmithkline trading services limited - albiglutide - diabetes mellitus, type 2 - drugs used in diabetes - eperzan is indicated for the treatment of type 2 diabetes mellitus in adults to improve glycaemic control as:monotherapywhen diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to contraindications or intolerance.add-on combination therapyin combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see section 4.4 and 5.1 for available data on different combinations).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - ambrisentan - tablet - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - ambrisentan - tablet - 10mg

European Union - English - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - fluticasone furoate - rhinitis, allergic, seasonal; rhinitis, allergic, perennial - nasal preparations, corticosteroids - adults, adolescents (12 years and over) and children (6-11 years). avamys is indicated for the treatment of the symptoms of allergic rhinitis.

European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - hepatitis b surface antigen - hepatitis b; immunization - vaccines - fendrix is indicated in adolescents and adults from the age of 15 years onwards for active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes for patients with renal insufficiency (including pre-haemodialysis and haemodialysis patients).

European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus inactivated, containing antigen equivalent to a/california/07/2009 (h1n1)-derived strain used nymc x-179a - influenza, human; immunization; disease outbreaks - influenza vaccines - prophylaxis of influenza caused by a (h1n1)v 2009 virus. pandemrix should only be used if the recommended annual seasonal trivalent / quadrivalent influenza vaccines are not available and if immunisation against (h1n1)v is considered necessary (see sections 4.4 and 4.8).pandemrix should be used in accordance with official guidance.

European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - a/indonesia/05/2005 (h5n1) like strain used (pr8-ibcdc-rg2) - influenza, human; immunization; disease outbreaks - vaccines - active immunisation against h5n1 subtype of influenza-a virus.this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared with h5n1 subtype strains.prepandrix should be used in accordance with official guidance.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - hepatitis a virus inactivated; hepatitis b virus surface antigen - suspension for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - hepatitis b virus surface antigen; hepatitis a virus inactivated - suspension for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - lamivudine - tablet - 100mg